exelixis

EXEL... sur google finance... elle vient de se reveiller..


a suivre

Pour info, les montants qu'exelixis vient de recevoir en upfront sont assez phenomenaux: 195 millions USD. On serait deja ravi avec cela pour le Napro. La valo de la societe est de/ 522 millions USD seulement. Et il y a quelques semaines Carl Icahn est rentré dans le capital. Le site mootley Fool la conseille comme le futur nouveau Genentech.

Enfin pas mal de signaux positifs.

Avis aux amateurs de sensations fortes, et en tant qu'investisseur de Nicox, je pense qu'il y en a bcp;)


BMS to pay Exelixis $240M for cancer drugs

Bristol-Myers Squibb has snatched up two Exelixis programs that GSK left behind when it ended its six-year collaboration with Exelixis. The development deal covers two cancer therapies--Exelixis' XL184, which is currently in Phase III trials for medullary thyroid cancer, and XL281, a treatment of patients with advanced solid tumor malignancies in Phase I development. Exelixis gets an upfront cash payment of $195 million for the development and commercialization rights to both programs, and BMS will make another $45 million milestone payment in 2009. The Wall Street Journal notes that this is one of the largest upfront payments a biotech has ever received (the Genzyme/Isis deal was the biggest, at $325 million).

The companies will co-develop and co-promote XL184 in the United States. Exelixis could receive sales performance milestones of up to $150 million and double-digit royalties on sales outside the U.S. If the company decides not to co-develop the drug, it will instead gain $295 million in development and regulatory milestones of up to $295 million in addition to double-digit royalties on XL184. BMS will exclusively develop and commercialize XL281. Exelixis could earn up to $315 million in development milestones, $150 million in sales performance milestones and double-digit royalties sales of any resulting product.

This is the third deal between the drug developers this year. Just last month BMS elected to develop Exelixis' experimental cancer therapy XL413, triggering a $20 million milestone, and in January BMS agreed to develop XL139, also for cancer.

"There have been many attempts to blend the best of big pharma with the best of biotech, and over the years Exelixis and Bristol-Myers Squibb have learned how to do just that. This new collaboration maximizes the capabilities and strengths of each partner and sets the stage for the aggressive development of XL184 and XL281," said Elliott Sigal, BMS's chief scientific officer and president of R&D.

...

Interesting Jules ! Thank you !

Je reçois aussi la newsletter de Motley Fool mais depuis quelque temps, à part Nicox, et vu le contexte, je veux plus m'investir et je ne l'ouvre plus tellement, lol

UPDATE 1-Exelixis drug
shows promise in brain cancer-study



38 pct of evaluated patients see tumor
shrinkage

* Exelixis shares rise 27 pct after hours

LOS ANGELES, May 14 (Reuters) - An experimental drug being
developed by Exelixis Inc (EXEL.O) and Bristol-Myers Squibb Co (BMY.N) was shown to shrink brain tumors in some patients,
according to interim results from a mid-stage study of the drug, known as
XL184.

Shares of Exelixis rose 27 percent after hours, while shares
of Bristol-Myers were unchanged.

Early results from a trial of 46 patients with advanced
glioblastoma multiforme, the most common and deadly type of brain cancer, were
released on Thursday as part of the American Society of Clinical Oncology's
conference program.

A summary of the findings, called an abstract, said 26 patients
have been assessed at four weeks after treatment. Ten of them, or 38 percent,
had tumor shrinkage of at least 50 percent, including one patient who had a 100
percent reduction in tumor size.

Nine patients had tumor measurement changes ranging from plus
24 percent to minus 49 percent and seven had at least a 25 percent increase in
tumor burden, according to the abstract.

Of 17 patients who had not received prior anti-angiogenic
treatment, nine had at least a 50 percent reduction in tumor burden.

Exelixis partnered with Bristol-Myers last year to develop
two experimental cancer drugs, including XL184, which is also being tested for
thyroid cancer and non-small cell lung cancer.

More details of the study will be released at ASCO's annual
meeting later this month.

Shares of Exelixis, which closed at $4.42 on the Nasdaq, were
higher at $5.60 after hours. (Reporting
by Deena Beasley, Editing by Steve Orlofsky)

Petite news ci dessus pour ceux que cela interesse. Pas mal de molecules dans les différentes phases et quelques partnerships interessant.

A suivre....

Exelixis and
Sanofi-aventis Sign Global License Agreement for XL147 & XL765 and Launch
Broad Collaboration for Discovery of PI3K Inhibitors




Exelixis
to Receive $140 Million Upfront Payment and Guaranteed Research Funding



SOUTH SAN FRANCISCO,
Calif.--(BUSINESS WIRE)--Sanofi-aventis (PARIS:SAN) and (NYSE:SNY)
and Exelixis, Inc. (Nasdaq:EXEL) today announced a global license agreement for
XL147 and XL765 and a broad collaboration for the discovery of inhibitors of
phosphoinositide-3 kinase (PI3K) for the treatment of cancer. Activation of the
PI3K pathway is a frequent event in human tumors, promoting cell proliferation,
survival and resistance to chemotherapy and radiotherapy. Under the license,
sanofi-aventis will have a worldwide exclusive license to XL147 and XL765,
which are currently in phase 1 and phase 1b/2 clinical trials, and will have
sole responsibility for all subsequent clinical, regulatory, commercial and
manufacturing activities. Exelixis will participate in conducting ongoing and
potential future clinical trials and manufacturing activities.

Under the discovery collaboration,
Exelixis and sanofi-aventis will combine efforts in establishing several
pre-clinical PI3K programs and jointly share responsibility for research and
preclinical activities related to isoform-selective inhibitors of PI3K. Sanofi-aventis
will have sole responsibility for all subsequent clinical, regulatory,
commercial and manufacturing activities of any products arising from the
collaboration; however, Exelixis may be responsible for conducting certain
clinical trials.

Sanofi-aventis will pay Exelixis
aggregate upfront cash payments of $140 million under the license and
collaboration. Exelixis will also receive guaranteed research funding of $21
million over a three year research term under the collaboration. For the
license and the collaboration, Exelixis will be eligible to receive
development, regulatory and commercial milestones of over $1 billion in the
aggregate, as well as royalties on sales of any products commercialized under
the license or collaboration.

“Sanofi-aventis has a track
record of success in commercializing innovative cancer therapies and is deeply
committed to advancing the care of cancer patients,” said George A. Scangos,
Ph.D., president and chief executive officer of Exelixis. “We believe that
their expertise and resources will enable us to move aggressively in advancing
the development of XL147 and XL765 and other potential PI3K inhibitors. The
data generated to date in the XL147 and XL765 clinical programs suggest that
these compounds may have utility in treating diverse cancers. Sanofi-aventis
and Exelixis are committed to realizing the full potential of these compounds
and other PI3K inhibitors to provide cancer patients with new treatment
options.”

The effectiveness of the
license and collaboration is subject to antitrust clearance under the
Hart-Scott-Rodino Antitrust Improvements Act and other customary regulatory
approvals.

Oral Presentations

Clinical data from the
phase 1 trials of XL147 and XL765 will be presented at the 2009 American
Society of Clinical Oncology Annual Meeting, which will be held from May 29 to
June 2, 2009 in Orlando, Florida:

• “Phase 1 dose-escalation study of XL147, a
  PI3K inhibitor administered orally to patients with solid tumors” will be
  presented on Monday, June 1, 2009, starting at 1:30 p.m. local time
  (Abstract #3500)
  
• “A Phase 1 dose-escalation study of the
  safety, pharmacokinetics (PK) and pharmacodynamics of XL765, a
  PI3K/TORC1/TORC2 inhibitor administered orally to patients (pts) with
  advanced solid tumors” will be presented on Monday, June 1, 2009 starting
  at 2:00 p.m. local time (Abstract #3502)
  

XL147 and XL765 target PI3K, which plays an
important role in cell proliferation and survival. XL765 also inhibits the
mammalian target of rapamycin (mTOR), which can be activated via upregulation
of PI3K, or via PI3K-independent mechanisms. mTOR is frequently activated in
human tumors and plays a central role in tumor cell proliferation



et cela continue, pour info, capi de 480 millions d'eur, ca vaut moins que Nicox. Vu les derniers upfronts touchés ca commence à devenir interessant.

A bon entendeur...

Jules

beau deal sur une phase I .......... imaginez ce que ca pourrait faire sur cox

Hello,


A suivre Exelixis, je ne sais pas ce que Seb en pense mais je pense que graphiquement, c'est plutôt sympa. Phase II?

Elle a toujours un pipeline assez impressionnant avec de nombreux partenaires, je reve d'en avoir un pareil pour Cox un jour

Et la valorisation est de 830 millions de USD seulement. Cela reste raisonnable en comparaison des perspectives. Plusieurs passages de phase anticipé en 2011.